In response to a rejected manuscript, the editor-in-chief received an email from an individual within the same laboratory expressing relief over the rejection. The writer, formerly listed as an author, disclosed misgivings about the study, specifically noting that the effect of the described biological mechanism was less than 1%. This individual opposed the submission of the manuscript, leading to the removal of their name from the author list by the lead author.
The Committee on Publication Ethics (COPE) provides guidance in such situations. While the letter does not explicitly state whether the concerns are related to an academic dispute or potential dishonesty in the interpretation of data, COPE emphasizes the editor's duty to actively pursue misconduct even if the manuscript is not published. Editors are considered privileged whistleblowers and play a crucial role in upholding the integrity of the scholarly publishing process.
To navigate this situation, the journal should seek clarification from the letter writer regarding the nature of the disagreement. It is essential to distinguish between genuine scientific disputes over data interpretation and potential misconduct. If the disagreement is of a scientific nature, the author retains the right to submit the manuscript for publication. However, if there are indications of misconduct, further investigation is warranted.
COPE recommends involving individuals who were part of the research in the writing process to ensure accurate attribution and accountability. The journal should carefully assess the details provided by the letter writer and, if necessary, initiate a thorough investigation in collaboration with the author of the manuscript.
Maintaining transparency and adherence to ethical standards is paramount in addressing such allegations. The journal should communicate openly with all parties involved, treating the matter with sensitivity while upholding the principles of academic integrity.